Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
4.720
+0.160 (3.51%)
Jun 8, 2026, 4:00 PM EDT - Market closed
Bolt Biotherapeutics Employees
Bolt Biotherapeutics had 23 employees as of December 31, 2025. The number of employees decreased by 29 or -55.77% compared to the previous year.
Employees
23
Change
-29
Growth
-55.77%
Revenue / Employee
$282,565
Profits / Employee
-$1,286,087
Market Cap
9.07M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 23 | -29 | -55.77% |
| Sep 30, 2025 | 40 | -12 | -23.08% |
| Dec 31, 2024 | 52 | -48 | -48.00% |
| Dec 31, 2023 | 100 | 6 | 6.38% |
| Dec 31, 2022 | 94 | 3 | 3.30% |
| Dec 31, 2021 | 91 | 26 | 40.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AIM ImmunoTech | 21 |
| Imunon | 20 |
| NuCana | 12 |
| Aprea Therapeutics | 8 |
| Ernexa Therapeutics | 7 |
| Quoin Pharmaceuticals | 6 |
| Kairos Pharma | 4 |
| Addex Therapeutics | 2 |
BOLT News
- 11 days ago - Bolt Biotherapeutics initiated with a Buy at Rodman & Renshaw - TheFly
- 27 days ago - Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 27 days ago - Bolt Biotherapeutics Quarterly report: Q1 2026 - Filings
- 27 days ago - Bolt Biotherapeutics Earnings release: Q1 2026 - Filings
- 5 weeks ago - Bolt Biotherapeutics Proxy statement: Proxy filing - Filings
- 5 weeks ago - Bolt Biotherapeutics Proxy statement: Proxy filing - Filings
- 3 months ago - Bolt Biotherapeutics reports Q4 EPS ($3.84), consensus ($5.52) - TheFly
- 3 months ago - Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update - GlobeNewsWire